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Early posttransplant tryptophan metabolism predicts long-term 
outcome of human kidney transplantation  
 
 
Vavrincova-Yaghi D, Seelen MA, Kema IP, Deelman LE,  
van der Heuvel M, Breukelman H, van den Eynde BJ, Henning RH, van 








Background: Chronic transplant dysfunction (CTD) is the leading cause of long-term loss 
of the renal allograft. So far, no single test is available to reliably predict the risk for CTD. 
Monitoring of tryptophan metabolism through the enzyme Indoleamine 2.3-dioxygenase 
(IDO) has been previously proposed to predict acute rejection of human kidney transplants. 
Here we investigate the potential of IDO to predict the long-term outcome of human kidney 
transplantation.  
 
Methods: During the 2 year follow-up blood, urine and kidney biopsies were collected from 
48 renal transplant patients. Concentrations of kynurenine and tryptophan in serum and 
urine were measured 2 weeks, 6 months and 2 years after transplantation. Kynurenine to 
tryptophan ratio (kyn/trp) was calculated as an estimate of IDO activity. To evaluate the 
histological changes and IDO expression, PAS staining and immunohistochemistry for IDO 
was performed on biopsies taken at 6 months and at 2 year follow-up. Correlation analysis 
between tryptophan, kynurenine, kyn/trp ratio, clinical data and immunohistochemistry was 
performed. 
 
Results: Urine IDO activity 2 years after transplantation was increased as compared to 2 
week values, whereas serum IDO activity decreased. In 2 year biopsies IDO expression was 
found in infiltrating inflammatory cells and in the glomeruli. The amount of IDO staining 
did not correlate with the histologic damage in the renal biopsies, nor with the levels of 
tryptophan, kynurenine and kyn/trp ratio in serum and urine. Serum level of kynurenine 6 
months after transplantation predicted the serum creatinine 2 years after transplantation. 
Additionally, the urine level of tryptophan 2 weeks after transplantation predicted the serum 
creatinine 6 months and the estimated creatinine clearance 2 years after transplantation.  
 
Conclusion: Early serum and urine levels of tryptophan and kynurenine predicted the 2 year  
outcome in patients after transplantation. Therefore, these parameters might offer a novel 








The short-term outcome of renal transplantation has improved during the past 20 
years. The introduction of cyclosporine in the early 80’s and the use of newer and a 
combination of immunosuppressive drugs such as mycophenolate mofetil and mTOR 
(mammalian target of rapamycin) inhibitors have substantially increased the rate of short-
term graft survival1. However, long-term graft survival has not noticeably improved2. 
Among all causes of long-term graft failure, chronic transplant dysfunction (CTD) is the 
most common indication for re-transplantation1. The cause of CTD is multifactorial, with 
alloresponsiveness, diabetes mellitus, hypertension and nephrotoxicity of 
immunosuppressants having a role herein3-5. Clinically, hypertension, increased levels of 
serum creatinine and proteinuria are found in the patients with signs of CTD6. The definite 
diagnosis requires histological analysis of a kidney biopsy in which interstitial fibrosis, 
tubular atrophy and glomerulosclerosis are indicators for CTD7. Although needle biopsy of 
the graft is the most sensitive diagnostic method, there is a 5-10% risk of biopsy-associated 
complications8, such as hematoma, infections (including sepsis and peri-renal abscess) and 
even loss of the renal graft9. 
As currently no single test is available to accurately predict the risk for CTD, the 
search for a suitable biomarker for CTD is still ongoing. In contrast to biopsies, such a 
marker would allow close monitoring of the development of CTD, especially in high risk 
patients. Consequently, the use of renal graft biopsy for graft monitoring may be 
minimized. Additionally, immunosuppressive therapy could be tailored according to the 
individual risk profile10. 
 Monitoring of tryptophan (trp) metabolism through the enzyme Indoleamine 2.3-
dioxygenase (IDO) has been previously proposed to predict acute rejection in renal 
transplant patients.  IDO11 catalyzes the initial and rate-limiting step of tryptophan 
oxidative catabolism with formation of several intermediaries, collectively referred to as 
kynurenines (kyn)12;13. The rate of tryptophan degradation, expressed as the kyn/trp ratio, 
has been used as a good estimate of enzymatic activity of IDO14;15.  
IDO has been documented to be critically involved in establishing immune tolerance 
against paternal antigens in pregnant mice16 and in inducing T-cell unresponsiveness11;17;18. 
Moreover, several studies indicate IDO activity or levels of its substrate and/or metabolites 
to associate with or predict acute rejection. Brandacher et al.19 documented elevated serum 
and urinary kyn/trp ratios during acute rejection of human kidney transplants. Further, 
Lahdou et al.20 found that increased pre-transplantation serum kynurenine levels predict 
acute kidney allograft rejection in humans. Additionally, IDO activity correlates with the 
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severity of chronic kidney disease13. There is yet no data regarding IDO activity or 
tryptophan metabolism in relation to the development of CTD or in long-term, 
uncomplicated renal transplantation. As a first step towards assessing the potential use of 
IDO activity as a biomarker in patients with CTD, we analyzed the levels of tryptophan and 
kynurenines in both serum and urine samples during a follow-up period of 2 years in kidney 
transplant patients. Moreover, level of rejection (Banff score) and IDO expression in renal 
biopsies was assessed using (immuno)histochemistry and correlation and multivariate 












Material and Methods 
Study design and patient population 
Forty eight patients (thirty two male and sixteen female, aged between 18 and 70 years), 
receiving a kidney transplant were included in a 24 month, prospective, randomized trial. 
The immunosuppressive treatment prior to the transplantation and during the follow-up was 
previously described2. Briefly, the peri-operative immunosuppressive regimen consisted of 
20 mg badiliximab i.v. prior to transplantation and on day 4 and two doses of 50 mg 
prednisolone i.v. during the first 48 hrs. During the first 6 months after transplantation, all 
patients received oral prednisolone (P) and triple-drug therapy consisting of cyclosporine A 
(CsA), mycophenolic sodium (MPS) and everolimus (EVL) (Table 1). After 6 months, the 
patients were randomized to double therapy with P/CsA, P/MPS, or P/EVL. Patients with 
histologic features of rejection continued on the triple-drug medication. 
Immunosuppressive drug exposure was closely monitored and its level was adjusted when 




Table 1. Immunosuppressive therapy during the follow up. During the first six months after 
transplantation all patients received triple therapy consisting of CsA, MPS and EVL. The drug 
regimen thereafter consisted of double therapy with P/CsA, P/MPS, or P/EVL or continuation of the 
triple-drug medication (triple therapy). P-prednisolone; CsA-cyclosporine A; MPS-mycophenolate 
sodium; EVL-everolimus 
 
first 6 months after transplantation    after 6 months 
 triple therapy (CsA+MPS+EVL)   P/CsA       P/MPS      P/EVL   triple therapy  




Serum and urine from these patients were collected at 2 weeks (2 wk), 6 months (6 mo) and 
2 years (2 yrs) after transplantation. Clinical parameters (blood pressure, body weight) as 
well as serum creatinine and albuminuria were measured at each time point. Estimated 
creatinine clearance was calculated according to the Cockroft-Gault formula (140 – age) x 




Tryptophan and kynurenine measurement  
The concentration of tryptophan and kynurenines in serum and urine was measured by a 
high-throughput on-line solid-phase extraction-liquid chromatographic-tandem mass 
spectrometer (XLC-MS/MS), as described earlier21. Briefly, fifty microliters of serum or 
urine were pre-purified by automated on-line solid-phase extraction, using strong cation 
exchange (PRS, propylsulphonic) cartridges. Chromatographic separation of the analytes 
and deuterated analogues occurred by C18 reversed phase chromatography. Mass 
spectrometric detection was performed in the multiple reaction-monitoring mode using a 
quadrupole tandem mass spectrometer with positive electrospray ionization. Detection limit 
was 30 nmol/l for tryptophan and 1 nmol/l for kynurenines. Finally, kynurenine/tryptophan 
(kyn/trp) ratio was calculated as an indirect estimate of IDO activity. 
 
Histology and Immunohistochemistry 
PAS staining was performed on biopsies taken at 6 months and at 2 year follow-up, 
according to the standard protocol.  
Immunohistochemistry for IDO was performed on biopsies taken at 6 months and at 2 years 
after transplantation. Normal kidneys were used as controls. Biopsies were dewaxed and 
subjected to antigen retrieval by 15 min incubation in 0.1M Tris/HCl buffer, pH 9.0, at 
80C. Mouse hybridoma anti-IDO primary antibody was used to assess the IDO expression. 
For immunohistochemistry, a three-step immunoperoxidase technique was used, according 
to standard techniques. Peroxidase activity was developed using 3, 3’-diaminobenzidine 
tetrachloride and H2O2. The cortical staining was measured using an Aperio-Image Scope 
based protocol and these values were further used in the correlation analysis.  
 
Statistical analysis  
Data are presented as mean ± SEM in case of normal distribution and as median 
(interquartile range) in case of skewed distribution. Significance was tested with the 
ANOVA for repeated measures followed by a least significant difference post hoc test, or 
with the Friedman test, as appropriate (SPSS). The potential relationships between 
tryptophan and kynurenine concentrations and kyn/trp ratio and clinical parameters were 
analyzed using Pearson’s parametric correlation test or Spearman’s non-parametric test as 
appropriate (SPSS). Multivariate linear regression analyses with forward stepwise 
procedure were performed to identify significant predictors of long-term renal outcome 
(plasma creatinine and albuminuria as dependent variables) among the concentrations of 






(independent variables). To avoid multicollinearity, the independent variables which were 
in correlation were excluded from data set and included to another data set where no inter-





Patients, assessment of the biopsies and clinical follow-up 
Table 2 gives an overview of the demographic characteristics of the patients.  
 
 
Table 2. Demographic characteristics of the patients 
 
Number of patients (male/female)    48 (32/16) 
Age in years (mean ± SEM)     49.2 ± 2.0 
Cause of end-stage renal disease (number of patients) 
  Glomerulonephritis     12 
  Polycystic kidney disease    10 
  Urological (postrenal) causes    7 
  Hypertensive nephropathy     3 
  Vascular       2 
  Diabetes mellitus     1 
  Other      13 
Donor (number of patients) 
  Living nonrelative donor    10 
  Living relative donor    9 
  Cadaveric donor     29 




Body weight, blood pressure, serum creatinine and albuminuria were monitored during the 
2 year follow up. These data are depicted in Table 3. Body weight increased significantly at 
2 years as compared to 2 week values. There were no significant changes in systolic blood 
pressure between all three time points however diastolic blood pressure was significantly 
elevated at 6 months and 2 years after transplantation, compared to the values at 2 weeks 






months after transplantation and remained at this level untill the end of the follow-up. A 
small but significant increase in albuminuria was seen at 6 months and 2 years after 
transplantation, compared to the second posttransplantational week. There were no 
significant differences between the four arms of immunosuppressive treatments (data not 
shown). 
 
Table 3.  Clinical parameters, serum creatinine and albuminuria during the follow-up. Data are 
expressed as mean ± SEM in case of normal distribution and as median (interquartile range) in case of 
skewed distribution; * p<0.05 versus 2 weeks.  
     2 weeks  6 months 2 years 
Body weight (kg)    74.4 ± 2.0 79.4 ± 2.1 81.0 ± 2.1*  
Systolic blood pressure (mmHg)  143.6 ± 2.8 145.4 ± 2.3 150.4 ± 1.9 
Diastolic blood pressure (mmHg)  81.1 ± 1.5 90.7 ± 2.1* 91.1 ± 1.6* 
Mean arterial pressure (mmHg)  102.0 ± 1.7 109.0 ± 1.9* 110.9± 1.8* 
Serum creatinine (µmol/l)   164 (332)  118.5 (48.2)* 114 (68)* 
Creatinine clearance (ml/min)  49.4 (37.8) 72.5 (28.9) * 65.2(33.8)* 
 




Based on histological analysis of the renal biopsy at 6 months follow-up, from the 48 
patients studied, 3 patients suffered from acute rejection (Banff score 1A), 5 patients were 
on the borderline of acute rejection, 15 patients showed slight reactive changes and 15 
patients did not show any significant histological changes. For six patients no biopsy was 
performed. Four biopsies showed no adequate or no kidney tissue. 
Table 4 depicts the results of the histological analysis at 2 year follow-up. Two patients 
showed clear signs of acute rejection (Banff 1A), 25 patients showed a borderline acute 
rejection pattern and 23 patients showed various degrees of interstitial fibrosis and tubular 
atrophy (IFTA). In 15 patients both signs of borderline acute rejection as well as IFTA were 
found. No significant changes were found in 10 biopsies. For 3 patients no biopsy was 
available or the biopsy was inadequate.  
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Table 4. Histologic changes at 2 years. From the 48 patients included, for 3 patients no biopsy was 
available. IFTA = interstitial fibrosis and tubular atrophy. 
 
Histologic changes     Number  
Acute rejection Banff 1A    2  
Borderline acute rejection     25  
IFTA      23 
IFTA + Borderline acute rejection   15 




Serum tryptophan, kynurenine and kyn/trp ratio 
In comparison with 2 weeks after transplantation, the serum level of tryptophan was 
increased at 6 months and 2 years after transplantation and slightly decreased at 2 years in 
comparison with 6 months (Figure 1A, p<0.05). Serum level of kynurenine increased at 6 
months as compared to 2 weeks and returned to the level of the 2 week by 2 years after 
transplantation (Figure 1B, p<0.05). Consequently, the serum IDO activity calculated as 
kyp/trp ratio was not changed at 6 months after transplantation as compared to the 2 weeks 
level and decreased significantly at 2 years (Figure 1C, p<0.05). No significant differences 
were found in serum tryptophan, kynurenine and kyn/trp ratio between the four 
immunosuppressive treatments (data not shown). In summary, IDO activity in serum is 
decreased at 2 years post-transplantation as compared to 2 week level. 
 
Urine tryptophan, kynurenine and kyn/trp ratio 
We also determined urine concentrations of tryptophan, kynurenine and kyn/trp ratio in our 
patients. The level of tryptophan at month 6 decreased significantly compared to week 2 
(Figure 2A, p<0.05) and remained stable at 2 years post-transplantation. The urine level of 
kynurenine decreased significantly at 6 months compared to week 2 (Figure 2B, p<0.05). 
Consequently, no change was observed in kyn/trp ratio from week 2 to 6 months. However, 
the kyn/trp ratio did significantly increase at 2 years in comparison with both 2 weeks and 6 
months (Figure 2C, p<0.05). No significant differences were found in urine tryptophan, 
kynurenine and kyn/trp ratio between the four immunosuppressive treatments (data not 
shown). In conclusion, IDO activity in urine is increased at 2 years post-transplantation as 



























Figure 1. Changes in serum levels of 
tryptophan, kynurenine and kyn/trp 
ratio during the 2 years follow-up. 
The level of tryptophan (A) increased at 
month 6 after transplantation and 
remained increased thereafter. The level 
of kynurenine (B) increased at month 6 
and again decreased at 2 years. The 
kyn/trp ratio (C) decreased during the 
follow-up. * p<0.05 vs 2 wk; # p<0.05 
vs 6 mo; trp, tryptophan; kyn, 
kynurenine; wk, weeks; mo, months; 
yrs; years 






































































We further investigated the expression of IDO protein in the 6 month- and 2 year-biopsies, 
using immunohistochemistry. In normal kidneys, a very limited expression of IDO was 
found in some distal tubular epithelial cells. In the 6 month-biopsies of the patients with 
acute rejection, a clear expression of IDO was found in the infiltrating inflammatory cells 
that morphologically resembled macrophages and dendritic cells (Figure 3A). There was 
also some expression in glomerular (mostly endothelial) cells (Figure 3B). In the 2 year 
biopsies of the patients with signs of chronic damage (IFTA), IDO expression was found 
around the atrophic tubules (Figure 3C). There was also a variable amount of glomerular 
staining, with some glomeruli showing strong expression of IDO in cells morphologically 
resembling endothelial cells and mesangial cells (Figure 3D). A very limited expression 
was found in the tubular epithelial cells. 
Figure 2. Changes in urine levels of 
tryptophan, kynurenine and 
kyn/trp ratio during the 2 years 
follow-up. The level of tryptophan 
(A) decreased at month 6 and 
remained stable thereafter. The level 
of kynurenine (B) decreased at month 
6 after transplantation. The kyn/trp 
ratio (C) increased at year 2. * p<0.05 
vs 2 wk; # p<0.05 vs 6 mo; trp, 
tryptophan; kyn, kynurenine; wk, 








Figure 3. Localization of IDO in acute rejection (A, B) and chronic transplant damage (C, D). 
Arrows indicate positive cells, including interstitially located inflammatory cells (black arrows), 
glomerular endothelial cells (dashed black arrows) and mesangial cells (red arrow).  
 
 
The amount of IDO staining, as assessed by morphometric analysis (data not shown), did 
not correlate with the histologic damage in the renal biopsies, nor with the levels of 
tryptophan, kynurenine and kyn/trp ratio in serum and urine.  
 
The serum level of kynurenine 6 months after transplantation predicted the serum 
creatinine at 2 years after transplantation 
Both serum kynurenine level and kyn/trp ratio at 6 months after transplantation correlated 
with the serum creatinine at 2 years after transplantation (Figure 4A, R = 0.444, Figure 4B, 
R = 0.410, p<0.05, respectively). Moreover, both serum kynurenine level and kyn/trp ratio 
at 6 months correlated with the serum creatinine at the same time point (R = 0.548, R = 
0.516, p<0.05, respectively). Multiple regression analyses identified serum kynurenine 
level at 6 months as the only independent predictor for serum creatinine at 2 years (best 
fitting model: serum creatinine 2 years = 85.3 + 19.8 x kynurenine 6 months; R = 0.336; 
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p<0.05), when serum tryptophan 2 weeks, kynurenine 2 weeks and kynurenine 6 months 
were included as independent factors.  
We did not find correlations between tryptophan or tryptophan metabolites levels and the 

















Figure 4. The correlations between serum levels of kynurenine, kyn/trp ratio and serum 
creatinine. The level of kynurenine 6 months after transplantation correlated with the serum 
creatinine 2 years after transplantation (A). The serum kyn/trp ratio 6 months after transplantation 
correlated with the serum creatinine 2 years after transplantation (B). p<0.05; mo, months; yrs, years 
  
kynurenine 6 mo (mol/l)






















300 A R= 0.444
p< 0.05
kyn/trp ratio 6 mo 






























The urine level of tryptophan 2 weeks after transplantation predicted the serum creatinine 
at 6 months and the estimated creatinine clearance 2 years after transplantation 
We found that the urine tryptophan level and kyn/trp ratio at week 2 after transplantation 
correlated with the serum creatinine at month 6 and year 2 after transplantation, in the case 
of tryptophan the correlation being negative (Figure 5A, R = -0.281, Figure 5B, R = 0.341, 
Figure 5C, R = -0.319, Figure 5D, R = 0.326, p<0.05, respectively). Additionally, urine 
tryptophan level at 2 weeks correlated with estimated creatinine clearance 2 years after 
transplantation (R = 0.403, p<0.05). Moreover, both urine tryptophan and kynurenine levels 
at week 2 correlated with the albuminuria at year 2 after transplantation (Figure 5E, R = 
0.285, Figure 5F, R = 0.365, p<0.05, respectively). Additionally, urine kyn/trp ratio at 
month 6 correlated with the albuminuria at year 2 after transplantation (Figure 5G, R = 
0.342, p<0.05). Multiple regression analyses identified urine tryptophan level at 2 weeks as 
the only independent predictor for serum creatinine at month 6 and for estimated creatinine 
clearance at year 2 (best fitting model: serum creatinine 6 months = 116.2 - 0.49 x 
tryptophan 2 weeks; R = 0.530; p<0.05; best fitting model: estimated creatinine clearance 2 
years = 52.4 + 0.36 x tryptophan 2 weeks; R = 0.497; p<0.05;  ), when urine tryptophan 2 
weeks, kyn/trp ratio 2 weeks, tryptophan 6 months and kyn/trp ratio 6 months were 
included as independent factors.  
Thus, the urine tryptophan levels at 2 weeks significantly predicted the higher serum 
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48 E R= 0.285
p< 0.05
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Figure 5. The correlations between 2 weeks urine tryptophan, kyn/trp ratio and serum 
creatinine and albuminuria. The urine tryptophan level 2 weeks after transplantation negatively 
correlated with the serum creatinine 6 months after transplantation (A). The urine kyn/trp ratio at 
week 2 after transplantation correlated with the serum creatinine at month 6 after transplantation (B). 
The urine tryptophan level 2 weeks after transplantation negatively correlated with the serum 
creatinine 2 years after transplantation (C). The urine kyn/trp ratio at week 2 after transplantation 
correlated with the serum creatinine at year 2 after transplantation (D). The urine tryptophan level 2 
weeks after transplantation correlated with the albuminuria 2 years after transplantation (E), as well as 
the urine kynurenine level 2 weeks after transplantation (F). The urine kyn/trp ratio 6 months after 
transplantation correlated with albuminuria 2 years after transplantation (G).  p<0.05; trp, tryptophan; 
kyn, kynurenine; wk, weeks; mo, months; yrs, years; hrs, hours  
 
  
kyn/trp ratio 6 mo




























The current study demonstrates that the serum and urine levels of tryptophan and 
kynurenine measured early after renal transplantation (i.e. at 2 weeks and 6 months) predict 
long-term renal outcome after transplantation, as assessed by serum creatinine and 
albuminuria in patients without overt CTD. The progressive decline in the renal function 
and the development of proteinuria and hypertension, are indicators alerting the clinician to 
the presence of CTD6. A biomarker which could predict these changes years before may 
allow early identification of patients at high risk for development of CTD. Our data indicate 
that the analysis of tryptophan metabolism early after transplantation might contribute to 
early detection of CTD. 
Several studies suggested the changes in tryptophan, kynurenine and IDO activity 
to reflect the short-term outcome of kidney transplantation. Serum kyn/trp ratio is higher in 
non-rejecting renal allograft recipients in comparison with healthy volunteers19. Moreover, 
kyn/trp is rapidly increasing in recipients with acute rejection compared to non-rejectors as 
early as by day one post-transplant. Additionally, IDO-positive cells were detected in renal 
biopsy of rejecting patients but not of those who did not reject the graft19. It has also been 
shown that serum tryptophan and kynurenine levels predict acute rejection of human kidney 
transplant. The pre-transplant levels of serum kynurenine and tryptophan were increased in 
patients who went on to develop acute renal rejection compared to those who did not20. 
These and other findings22 indicate that IDO activity is induced during acute rejection. Up 
till now, there is a lack of information regarding IDO activity, expression and tryptophan 
catabolism in long-term post-transplant outcome. Schefold et al.13 analyzed tryptophan 
catabolism and IDO activity in a cohort of forty patients with chronic kidney disease with 
various backgrounds, such as diabetic and hypertensive nephropathy and 
glomerulonephritis. The serum tryptophan level was relatively unchanged, but IDO activity 
and serum levels of tryptophan catabolites (such as kynurenine, kynurenic acid and 
quinolinic acid) increased with the severity of chronic kidney disease. Furthermore, the 
levels of kynurenic and quinolinic acid correlated with serum creatinine, creatinine 
clearance and in the case of kynurenic acid, also with eGFR13. The induction of IDO in 
chronic kidney diseases may primarily be a consequence of chronic inflammation13.  
In our study, urine IDO activity 2 years after transplantation was increased as 
compared to 2 week values, whereas serum IDO activity decreased. Previously, little IDO 
expression was found in kidney biopsies without acute rejection approximately 2 weeks 
after transplantation19, whereas strong IDO expression was found in our study at 2 years 






reflects the increased expression of IDO in the transplanted kidney. However, no 
correlation was found between the amount of IDO staining and the kyn/trp ratio in urine, 
possible because not all the IDO protein in the kidney is enzymatically active. Earlier, 
Brandacher et al.19 documented IDO expression in acutely rejected renal grafts. IDO 
positive cells were identified in the mononuclear cell infiltrates and the tubular epithelial 
cells. In our study, the strongest expression was also found in the interstitial inflammatory 
infiltrates. Only weak expression was found in tubular epithelial cells and, as opposed to 
the study of Brandacher et al., glomerular staining in (mostly) endothelial cells was also 
documented. The reason for this difference is unclear; it may rely for instance on the time 
to biopsy (6 months in our study vs. weeks in the study of Brandacher), the differences in 
the anti-IDO antibody or the differences in the (induction) immunosuppressive medication. 
In the 2 year biopsies IDO expression followed a similar pattern, however stronger 
expression was noticed in (both endothelial and mesangial) glomerular cells. This pattern of 
IDO expression is not unexpected. IDO is known to be up-regulated in immunologically 
active cells (i.e., infiltrating mononuclear cells). Also, expression of IDO in endothelial 
cells at the foeto-maternal interface has been earlier documented23. Expression of IDO in 
mesangial cells has, to the best of our knowledge, not been reported so far. What role does 
exactly IDO play in these cells remains to be elucidated.  
In this study we describe for the first time the kinetics of the tryptophan 
metabolism during a 2 year follow up after kidney transplantation in humans. Moreover, we 
document that the levels of tryptophan and its metabolite kynurenine at week 2 and month 6 
can predict the long-term changes in serum creatinine and albuminuria. Hence, analyzing 
the combination of tryptophan, kynurenine and kyn/trp ratio early after the transplantation 
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